@Article{Cichoń2022,
journal="Dermatology Review/Przegląd Dermatologiczny",
issn="0033-2526",
volume="109",
number="5",
year="2022",
title="Conjunctivitis as a common adverse effect of dupilumab
in atopic dermatitis",
abstract="Dupilumab is a monoclonal antibody against the a subunit of the receptor for interleukin 4 and interleukin 13. It is the first biological drug registered in the world for the treatment of atopic dermatitis. Dupilumab turned out to be a milestone in the treatment of atopic dermatitis and an alternative to standard immunosuppressive drugs. In numerous multicenter studies, including real-life studies, it has been proven that dupilumab brings a significant improvement in subjective and objective clinical symptoms in atopic dermatitis. Conjunctivitis is one of the side effects of dupilumab treatment. It is estimated that it affects about 14% of patients with atopic dermatitis. The mechanisms leading to it are not yet fully understood.",
author="Cichoń, Mikołaj
and Sroka-Tomaszewska, Jowita
and Trzeciak, Magdalena",
pages="344--351",
doi="10.5114/dr.2022.125683",
url="http://dx.doi.org/10.5114/dr.2022.125683"
}